Elevated Serum Uric Acid Predicts Chronic Kidney Disease

2011 ◽  
Vol 342 (6) ◽  
pp. 461-466 ◽  
Author(s):  
Tamaki Yamada ◽  
Mitsuru Fukatsu ◽  
Tsuneya Wada ◽  
Sadao Suzuki ◽  
Takashi Joh
e-CliniC ◽  
2017 ◽  
Vol 5 (2) ◽  
Author(s):  
Jonathan Moula ◽  
Emma Sy. Moeis ◽  
Cerelia Sugeng

Abstract: Chronic kidney disease (CKD) is a global public health problem. The CKD Epidemiology Collaboration (CKD-EPI) equation is the most accurate result of GFR (eGFR) that has been evaluated in large varied populations and can be applied clinically in general. In CKD patient, uric acid excretion decreases linearly along the worsening renal function. This study was aimed to determine the relationship between serum uric acid level based on eLFGCKD-EPI value and eGFR CKD-EPI in non-dialysis CKD patients (male and female). This was an analytical study with a cross-sectional design using medical record data of CKD patients at Prof. Dr. R. D. Kandou Hospital from January to December 2016. There were 82 samples who met the inclusion criteria. The results showed that 45 of 54 males and 27 of 28 females with non-dialysis CKD had elevated serum uric acid levels. The correlation test between serum uric acid level and eLFG CKD-EPI value on males and females were P=0.0; r=-0.473 and P=0.0; r=-0,598 respectively. Conclusion: There was a significant negative relationship between serum uric acid level and eLFG CKD-EPI value in non-dialysis CKD patients for both sexes. Based on eLFGCKD-EPI value, most patients had elevated serum uric acid levels.Keywords: non-dialysis chronic kidney disease, serum uric acid, eLFG CKD-EPI Abstrak: Penyakit ginjal kronik (PGK) merupakan masalah kesehatan masyarakat global. Persamaan CKD-EPI (CKD Epidemiology Collaboration) adalah persamaan estimasi LFG (eLFG) yang paling akurat dan telah dievaluasi pada populasi beragam dalam jumlah besar dan dapat diterapkan pada penggunaan klinis secara umum. Pada pasien PGK, ekskresi asam urat menurun secara linier seiring dengan memburuknya fungsi ginjal. Penelitian ini bertujuan untuk mengetahui hubungan kadar asam urat serum berdasarkan nilai eLFGCKD-EPI dan nilai eLFG CKD-EPI pada PGK non-dialisis (PGK-ND) baik pada jenis kelamin laki-laki maupun perempuan. Jenis penelitian ialah analitik dengan desain potong lintang menggunakan data rekam medik pasien PGK di RSUP Prof. Dr. R. D. Kandou periode Januari-Desember 2016. Terdapat 82 sampel yang memenuhi kriteria inklusi. Hasil penelitian mendapatkan 45 dari 54 laki-laki dan 27 dari 28 perempuan dengan PGK-ND mengalami peningkatan kadar asam urat serum. Uji korelasi hubungan antara kadar asam urat serum dan nilai eLFGCKD-EPI pada jenis kelamin laki-laki dan perempuan masing-masing P=0,0; r=-0,473 dan P=0,0; r=-0,598. Simpulan: Terdapat hubungan negatif bermakna antara kadar asam urat serum dan nilai eLFGCKD-EPI pada kedua jenis kelamin. Pada sebagian besar pasien PGK-ND baik laki-laki mupun perempuan terdapat peningkatan kadar asam urat serum berdasarkan nilai eLFGCKD-EPI.Kata kunci: penyakit ginjal kronis non-dialisis, asam urat serum, eLFG CKD-EPI


2020 ◽  
Vol 27 (2_suppl) ◽  
pp. 35-45
Author(s):  
Andrea Tedeschi ◽  
Piergiuseppe Agostoni ◽  
Beatrice Pezzuto ◽  
Ugo Corra’ ◽  
Domenico Scrutinio ◽  
...  

Despite improvements in pharmacotherapy, morbidity and mortality rates in community-based populations with chronic heart failure still remain high. The increase in medical complexity among patients with heart failure may be reflected by an increase in concomitant non-cardiovascular comorbidities, which are recognized as independent prognostic factors in this population. Heart failure and chronic kidney disease share many risk factors, and often coexist. The presence of kidney failure is associated with incremented risk of cardiovascular and non-cardiovascular mortality in heart failure patients. Chronic kidney disease is also linked with underutilization of evidence-based heart failure therapy that may reduce morbidity and mortality. More targeted therapies would be important to improve the prognosis of patients with these diseases. In recent years, serum uric acid as a determinant of cardiovascular risk has gained interest. Epidemiological, experimental and clinical data show that patients with hyperuricaemia are at increased risk of cardiac, renal and vascular damage and cardiovascular events. Moreover, elevated serum uric acid predicts worse outcome in both acute and chronic heart failure. While studies have raised the possibility of preventing heart failure through the use of uric acid lowering agents, the literature is still inconclusive on whether the reduction in uric acid will result in a measurable clinical benefit. Available evidences suggest that chronic kidney disease and elevated uric acid could worsen heart failure patients’ prognosis. The aim of this review is to analyse a possible utilization of these comorbidities in risk stratification and as a therapeutic target to get a prognostic improvement in heart failure patients.


2013 ◽  
Vol 37 (3) ◽  
pp. 246-252 ◽  
Author(s):  
Ryota Yoshitomi ◽  
Akiko Fukui ◽  
Masaru Nakayama ◽  
Yoriko Ura ◽  
Hirofumi Ikeda ◽  
...  

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Shingo Nakayama ◽  
Michihiro Satoh ◽  
Takahisa Murakami ◽  
Yukako Tatsumi ◽  
Tomoko Muroya ◽  
...  

Abstract Background and Aims While previous studies have reported the association between serum uric acid (SUA) and chronic kidney disease (CKD) incidence, the sex differences in this association remain controversial. Therefore, we examined the association between SUA levels and CKD incidence in middle-aged adults stratified by sex using data from a large-scale health check-up. Method We analyzed information from the JMDC database, which included the annual health check-up data of Japanese employees and their dependents aged <75 years. Among those individuals, we analyzed data from 138,511 individuals without CKD, kidney disease, or a history of cardiovascular disease at baseline. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and/or proteinuria. We divided the participants into 9 and 7 groups according to SUA levels for men and women, respectively. A Cox model was applied to assess the adjusted hazard ratios (HRs) for CKD incidence in each SUA level group using an SUA concentration of 4.0–4.9 mg/dL as the reference after adjusting for age, body mass index, current or ex-smoker, current or ex-drinker, diabetes mellitus, dyslipidemia, systolic blood pressure, use of anti-hyperuricemic drugs, and baseline eGFR. Results The mean participant age was 44.1 years, and 29.6% were women. The mean SUA levels were 5.9 mg/dL and 4.1 mg/dL in men and women, respectively. During the mean follow-up period of 4.68 years, 12,589 participants developed CKD. The age-standardized incidence rates for CKD were 17.88/17.80 per 1000 person-years in men/women with SUA concentrations of 4.0–4.9 mg/dL, 209.76 per 1000 person-years in men with SUA ≥11.0 mg/dL, and 73.38 per 1000 person-years in women with SUA ≥ 9.0 mg/dL. The fully adjusted HRs (95% confidence interval [CI], P value) for CKD incidence in the groups with SUA concentrations of <4.0, 10.0–10.9, and ≥11.0 mg/dL compared with those with SUA of 4.0–4.9 mg/dL among men were 1.13 (1.01–1.26, P=0.030), 1.98 (1.32–2.97, P=0.0010), and 3.74 (1.68–8.35, P=0.0013), respectively. In women, the fully adjusted HRs for CKD incidence in the groups with SUA concentrations of <4.0, 8.0–8.9, and ≥9.0 mg/dL were 1.08 (1.01–1.16, P=0.032), 2.39 (1.07–5.35, P=0.034), and 3.20 (0.80–12.8, P=0.10), respectively. Similar results were observed when we performed the sensitivity analysis excluding 8,411 individuals with hypertensive treatment from the main analysis. The HRs for the outcomes caused by the onset of eGFR <60 mL/min/1.73 m2 or proteinuria separately were similar to those for the main results. Conclusion The results of the present study demonstrated an increased risk of CKD in men with SUA concentrations of <4.0 and ≥10.0 mg/dL and <4.0 and ≥8.0 mg/dL in women compared to those with SUA concentrations of 4.0–4.9 mg/dL after adjusting for various covariates. Both high and low SUA levels were risk factors for CKD in middle-aged men and women. Hyperuricemia was demonstrated to cause renal injury due to the intraluminal deposition of uric acid crystals in the renal collecting duct. Hyperuricemia may also induce endothelial dysfunction, activation of the renin-angiotensin system, and induction of inflammation and stimulation of vascular smooth muscle cell proliferation by the induction of cyclooxygenase-2. However, as uric acid is one of the most important antioxidants in human plasma, low SUA levels may increase the risk of CKD incidence through decreased antioxidant activity. These mechanisms are implicated in the pathogenesis of CKD caused by high and low SUA levels. In addition, the SUA levels and ranges associated with increased risks of CKD incidence differed by sex.


2010 ◽  
Vol 25 (11) ◽  
pp. 3593-3599 ◽  
Author(s):  
L. Cain ◽  
A. Shankar ◽  
A. M. Ducatman ◽  
K. Steenland

Author(s):  
Shahida Akhter ◽  
A. S. M. Rizwan

Background: Hyperuricaemia is a metabolic marker of decreased renal function in chronic kidney disease (CKD). It increases cardiovascular, cerebrovascular and mortality risk in patients with CKD. Objectives: To estimate serum uric acid level in different stages of CKD. Methods: The present study was a cross sectional analytical study and was conducted in the Department of Physiology, Dhaka Medical College, Dhaka from July 2012 to June 2013 on 300 participants. They were divided into group A (150 control healthy participants) and group B (150 diagnosed cases of CKD). Serum creatinine and serum uric acid levels were measured by auto analyzer in Department of Pathology, Dhaka Medical College. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine level by Modification of Diet in Renal Disease (MDRD) equation. For statistical analysis unpaired Student “t” test, one way ANOVA test, Bonferroni test, Pearson’s correlation coefficient (r) test and Linear regression were performed using SPSS for windows version 20. Result: In this study, serum uric acid level was significantly (p<0.05) higher and eGFR were significantly lower in study groups than that of control group. There was gradual rise of serum uric acid level in CKD subjects from stage I to V. A significant inverse correlation was observed between serum uric acid level and eGFR. Serum uric acid level increased 0.048 mg/dl for each ml/min/1.73m2 decrease of eGFR. Conclusion: This study concludes that serum uric acid level increases gradually in accordance with the higher stages of CKD. There is a negative correlation of serum uric acid with eGFR in all stages of CKD which was statistically significant (p<0.05). Screening of serum uric acid level in different stages of CKD may be beneficial for assessing renal damage as well as prediction of co-morbidities associated with it.


2019 ◽  
Vol 12 (4) ◽  
pp. 235-242 ◽  
Author(s):  
Wisit Kaewput ◽  
Charat Thongprayoon ◽  
Ram Rangsin ◽  
Prajej Ruangkanchanasetr ◽  
Tarun Bathini ◽  
...  

2017 ◽  
Vol 26 (1) ◽  
pp. 12-24
Author(s):  
ASM Tanim Anwar ◽  
Md Nizamuddin Chowdhury ◽  
Md Nazrul Islam ◽  
Parvez Iftekher Ahmed ◽  
Sohely Ahmed Sweety ◽  
...  

This was a hospital based prospective, interventional study which included CKD stage 3- 5 patients with higher level of uric acid (male>7mg/dl, female>6mg/dl). The objective of the study was to evaluate the effect of allopurinol on inflammatory markers in patients with chronic kidney disease (stage 3-5) with asymptomatic hyperuricaemia. One hundred and twenty patients were distributed in two groups. Sixty patients were placed in treatment group and sixty in control group. Purposive sampling technique was followed. In the study mean age was 49 (±9) years in treatment group and 45 (±11) years in control groups. Male were predominant in both groups. There were no significant difference in baseline characteristics between treatment group and control group (p>0.05). Sixty patients of treatment group were administered a dose of 100 mg/d of allopurinol. Follow up assessment was done at basally, at 4 months and at 8 month after starting treatment. No significant differences were seen between baseline SBP, DBP, Hb and HbA1c with 4th month and 8th month follow up in both treatment group and control group, but mean Hb was significantly decreased in control group from the baseline after 8 month. No significant change was found in case of mean ESR at 4th and 8th month in any group. But base line mean CRP was significantly reduced in treatment group and increased in control group at 4th and 8th month of follow up. Serum uric acid was decreased in treatment group while it was significantly raised from the base line at 4th month and 8th month in control group. While comparing between two groups results showed means of serum uric acid and CRP were significantly decreased in treatment group compared to control group after 8th month. There was a positive correlation between Uric Acid with CRP level after 8 month of allopurinol treatment although this finding was not statistically significant. So, allopurinol may have a protective role in CKD by decreasing serum uric acid level and reduction of inflammatory response in patients with chronic kidney disease stage 3 - 5 with asymptomatic hyperuricaemia.J Dhaka Medical College, Vol. 26, No.1, April, 2017, Page 12-24


Sign in / Sign up

Export Citation Format

Share Document